Bafna Pharmaceuticals Reports Strong FY26 Results

Bafna Pharmaceuticals net profit surged 167.30% year-on-year to Rs 11.34 crore in the fiscal year 2025-26.

Earnings Per Share (EPS) rose to Rs 4.69 from Rs 1.76 in the previous fiscal.

Reader Takeaway: Profitability boost and export growth are positive drivers; audit trail upgrade and GST litigation are key watch points.

What just happened

Bafna Pharmaceuticals announced its financial results for the fiscal year ending March 31, 2026. The company reported a significant jump in net profit, growing by 167.30% to Rs 11.34 crore. Revenue from operations saw a modest increase of 3.26% to Rs 150.62 crore. EBITDA also showed strong growth of 48.74% to Rs 20.70 crore. Export sales were a highlight, growing 31.29% to Rs 95.81 crore, now accounting for 64% of the company's total turnover. The company also achieved the 25% Minimum Public Shareholding (MPS) compliance ahead of the April 2, 2025 deadline.

Why this matters

The substantial increase in net profit and EBITDA indicates improved operational efficiency and cost management. The strong performance in export sales suggests successful market penetration and diversification, reducing reliance on domestic markets. The positive credit outlook from ICRA further bolsters investor confidence.

The backstory

In the previous fiscal year (FY2024-25), Bafna Pharmaceuticals had reported a net profit of Rs 3.97 crore on revenue from operations of Rs 145.86 crore. EBITDA stood at Rs 13.92 crore. The company has been working on strategic initiatives, including rationalizing its manufacturing facilities and expanding its product portfolio in international markets.

What changes now

The company's focus on modernizing its Grantlyon, Chennai facility and registering new products internationally is expected to drive future growth. The upgrade of accounting software to include an audit trail is a key compliance step. The promoter holding stands at 74.57% after an Offer for Sale (OFS) by SRJR Lifesciences LLP to meet MPS requirements.

Risks to watch

Auditors noted that the current accounting software lacks a mandatory audit trail (edit log). The company is upgrading its software to comply. Additionally, the auditors' report mentions pending Goods and Services Tax (GST) related litigation, which investors should monitor.

Peer comparison

While specific peer comparisons are not detailed in the filing, Bafna Pharmaceuticals' strong export focus and improved profitability metrics place it in a competitive position within the pharmaceutical sector. The company's growth in international markets and focus on R&D for new product registrations are key differentiators.

Context metrics (time-bound)

• FY2025-26: Revenue Rs 150.62 crore, EBITDA Rs 20.70 crore, Net Profit Rs 11.34 crore, EPS Rs 4.69.
• FY2024-25: Revenue Rs 145.86 crore, EBITDA Rs 13.92 crore, Net Profit Rs 3.97 crore, EPS Rs 1.76.
• Export Sales FY2025-26: Rs 95.81 crore (31.29% growth).
• Minimum Public Shareholding Compliance: Achieved April 02, 2025.
• ICRA Credit Outlook: Revised to Positive (Jan 23, 2026).

What to track next

Investors will be keen to track the progress on the accounting software upgrade and the resolution of GST-related litigation. Continued growth in export sales and new product filings will be key indicators of future performance.